Compare American Well Corp (AMWL) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Well Corp vs Incyte Corporation — how do they compare? American Well Corp trades at $12.56 (market cap $220.94M), while Incyte Corporation trades at $120.54 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 111.1× American Well Corp's market cap. Which is the better fit depends on your goals.
| AMWL | INCY | |
|---|---|---|
Market Cap | $220.94M | $24.54B |
Sector | Health | Health |
52-Week High | $13.58 | $129.93 |
52-Week Low | $3.78 | $81.61 |
Enterprise Value | $27.98M | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMWL trades at $12.93, down 4.79% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q2 2026 revenue of $52 million, beating estimates, and continues to narrow losses, targeting cash-flow breakeven by Q4 2026. Recent news includes a key executive joining Amazon's healthcare unit, highlighting strategic relevance.
Outlook hinges on achieving profitability targets amid declining revenues. Opportunities include operational efficiency gains and high-profile partnerships, but risks persist from sustained net losses and competitive pressures. Analyst consensus is cautious with 67% hold ratings.
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Well Corp
American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others and its Health System Modules include Acute Behavioral Health, ED Triage, Pediatrics and Telestroke among others.
Read more on AMWL →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
